A Massachusetts-based biopharmaceutical company.

Historically, advancement of therapies for newly diagnosed prostate cancer provides been hindered by the slow progression of this disease. Predicated on our previous data, we were able to design a novel clinical approach that allows efficacy assessment at 24-36 a few months, stated Dr. Aguilar-Cordova. Protocol development was co-chaired by Drs. Theodore DeWeese, Seat of Radiation Oncology at Johns Hopkins, and Peter Scardino, Chief of Medical procedures and Chair of Urology at Memorial Sloan Kettering Cancer Center.Study Treatment and Design This international open-label, phase 2 study was conducted at 18 sites. Single-agent bortezomib is a treatment approved by the Food and Drug Administration for sufferers with mantle-cell lymphoma that has progressed after at least one initial treatment. Therefore, a precise cohort of patients with prior bortezomib treatment was one of them study, and the combination of both cohorts was representative of a broad population of individuals with relapsed or refractory mantle-cell lymphoma. Patients received single-agent ibrutinib administered orally at a daily dosage of 560 mg until progression of disease or until unacceptable levels of adverse events occurred.